News

Kelun-Biotech Secures Approval for Tagitanlimab in New Indication

Kelun-Biotech Secures Approval for Tagitanlimab in New Indication

Kelun-Biotech's Tagitanlimab Achieves Marketing Approval

Kelun-Biotech Biopharmaceutical Co., Ltd. has received significant news about the marketing authorization of its innovative drug tagitanlimab. This programmed cell death ligand 1 (PD-L1) directed monoclonal antibody is now approved to be used in combination with cisplatin and gemcitabine, specifically for the treatment of patients suffering from recurrent or metastatic nasopharyngeal cancer (NPC).

Clinical Study Highlights

The approval from the National Medical Products Administration (NMPA) relies on a comprehensive phase III clinical trial. This randomized, double-blinded, placebo-controlled study assessed the combined efficacy and safety of tagitanlimab when used alongside standard chemotherapy treatments. Led by Professor Shi Yuankai of the Cancer Hospital Chinese Academy of Medical Sciences, the study confirms the potential of this therapy to enhance patient outcomes.

Impressive Results in Patient Survival

According to the findings, data suggested that patients treated with tagitanlimab, cisplatin, and gemcitabine might experience enhanced progression-free survival (PFS) rates. The study showed that the median PFS for the drug combination was notably superior, with an impressive reduction in the risk of disease progression and mortality by 53%. The objective response rate (ORR) for this combination was 81.7%, compared to 74.5% for baseline chemotherapy.

Double the Duration of Response

Moreover, the results indicated that the median duration of response (DoR) for tagitanlimab was significantly longer — 11.7 months versus only 5.8 months for those in the control group. While median overall survival (OS) data is still being gathered, early trends suggest a favorable improvement for patients receiving the experimental therapy.

Second Indication Approved for Tagitanlimab

This marks the second indication for tagitanlimab, having previously gained approval for monotherapy in cases where patients experienced failure after prior treatments. Such recognition reinforces the drug's potential impact on treating NPC patients in different scenarios.

Leadership's Vision for the Future

Kelun-Biotech's CEO, Dr. Micheal Ge, expressed enthusiasm regarding this advancement, emphasizing the significance this new approval holds for patients battling NPC. He stated that this achievement reflects the company's dedication not just to scientific innovation but also fulfilling unmet clinical needs effectively.

Commitment to Continued Innovation

Looking into the future, Kelun-Biotech is determined to expand its research and development efforts, aiming to provide additional therapeutic options that can optimize patient care and enhance quality of life. The company is deeply invested in addressing critical medical needs on a broader scale.

About Kelun-Biotech

As a holding subsidiary of Kelun Pharmaceutical, Kelun-Biotech is focused on the R&D, manufacturing, and commercialization of advanced biological drugs and small molecules. The company is particularly dedicated to tackling major disease areas such as solid tumors, autoimmune conditions, and metabolic disorders. With over 30 innovative drug projects underway, Kelun-Biotech strives to lead in the innovative drug space while establishing a strong global presence in drug development.

Frequently Asked Questions

What is tagitanlimab used for?

Tagitanlimab is a PD-L1 monoclonal antibody used in combination with cisplatin and gemcitabine for treating recurrent or metastatic nasopharyngeal cancer.

What are the benefits of using tagitanlimab?

Tagitanlimab has been shown to improve progression-free survival, response rates, and duration of response compared to traditional chemotherapy.

Who led the clinical studies for tagitanlimab?

Professor Shi Yuankai of the Cancer Hospital Chinese Academy of Medical Sciences was the principal investigator for the clinical study assessing tagitanlimab.

Is tagitanlimab approved for other indications?

Yes, in addition to its recent approval for combination therapy, tagitanlimab was previously approved as a monotherapy for patients who were unsuccessful after 2L+ chemotherapy.

What is Kelun-Biotech's mission?

Kelun-Biotech aims to address unmet medical needs globally by advancing innovative therapies in various major disease areas.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TELUS Digital Shakes Up Dreamforce with Exclusive Session

Updated Category News Views 17

What's Cooking at Hotel Zetta? Ever see a company shake up an event like TELUS Digital is about to at Dreamforce 2026? Instead of the usual booth schmooze-fest at Moscone Center, these folks are camping at Hotel Zetta with a packed 'boutique' agenda. From September 15–16, they're rolling out serious insider sessions for the big brains in financial services, education,...

Continue Reading
Lundbeck's Bexicaserin Insights Rock Epilepsy Congress

Updated Category News Views 5

Breaking Down Bexicaserin's Dual Action Seems like Lundbeck's playing the long game with bexicaserin, and boy, are they shaking things up at the European Epilepsy Congress. This isn't your usual sit-back-and-watch situation. They're putting bexicaserin's dual mode of action under a magnifying glass, aiming to hit both sides of the brain's seesaw by increasing inhibitory...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 3

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Graphic Packaging Names Berardinelli as HR Executive

Updated Category News Views 5

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

Continue Reading
ITP Media's Bold Move: Ready for Asian Market Surge

Updated Category News Views 4

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Continue Reading
Hydrogen Mobility Gains Steam: Industry & Policy Unite

Updated Category News Views 3

The winds are changing, and this time, it's hydrogen that's blowing into town. Europe may just be on the brink of a major trucking overhaul, driven by a concoction of industry giants and supportive policies. The stage is set for hydrogen trucks to roll out by 2030, aiming to gut traditional fuel options and stack the odds in favor of zero-emission transport. Can you smell...

Continue Reading
Decoding Historic Home Buys: Tips for New Owners

Updated Category News Views 1

Realities Behind the Rustic Facade Picture this: you’re standing in front of a crumbling beauty with crown molding and character oozing from its very walls. Now what? It's easy to get swept away by the allure of a historic home, but there's gritty work to be done under those charming facades. Enter Debi Beiland of Limestone Properties over in Maysville, KY. She’s got...

Continue Reading
Greenberg Traurig Shines in 2026 Palm Beach Attorney List

Updated Category News Views 0

Legal Eagles Soar in the Sunshine State Right out of the gate, it looks like Greenberg Traurig's West Palm Beach office is getting all the spotlight. Twenty-one of their legal hotshots have clinched spots on Palm Beach Illustrated's 2026 'Top Lawyers' list. For those keeping score, that's a hefty nod in this competitive market. A Closer Look at the Selection Process Now,...

Continue Reading
Jim Morey Joins Pickleman's to Drive Expansion

Updated Category News Views 2

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Continue Reading
Russo-Rodriguez: A New Era in Florida Politics?

Updated Category News Views 3

A Political Shake-Up in Florida On a seemingly regular day in New Smyrna Beach, Frank Russo, the independent candidate for governor, decided to toss a wrench into Florida's political machine. By naming Rachel Rodriguez as his running mate, he's forging a new path that challenges entrenched party norms. This Russo-Rodriguez ticket is stirring the political pot,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Results from Landsbankinn’s Latest Covered Bond Exchange

Updated Category News Views 98

Overview of the Covered Bond Auction The recent covered bond auction held by Landsbankinn hf. brought exciting developments to the market. This was a pivotal moment for investors, as it involved a covered bond exchange offering, allowing existing holders of the series LBANK CB 25 to engage in a beneficial reassessment of their investments. Details of the Exchange Offering...

Continue Reading
Delightful Return of Little Debbie Ice Cream Bar Flavors

Updated Category News Views 337

Exciting Comeback of Little Debbie Ice Cream Bars As the warmth of summer approaches, it's time to indulge in a delightful treat. Little Debbie Ice Cream Bars are back, bringing joy to sweet-toothed fans everywhere. These delicious ice cream bars can now be found in the ice cream aisle of your nearest store, and they're sure to please both kids and adults alike. Tasty...

Continue Reading
Lorient Capital Welcomes Stephanie DeGennaro and John Cotcher

Updated Category News Views 152

Lorient Capital Expands Its Team with New Additions Lorient Capital, a renowned private investment firm focused on healthcare, is thrilled to announce the hiring of two key professionals to strengthen its dynamic team. The new team members are Stephanie DeGennaro, who takes on the role of General Counsel, and John Cotcher, who joins as Vice President of Compliance and HR...

Continue Reading
Exciting Developments in Vaultro Finance Presale Events

Updated Category News Views 223

Vaultro Finance Sees Unprecedented Demand for $VLT Tokens In an exciting turn of events, Vaultro Finance has achieved over 90% sales in its $VLT token presale, with only a mere 12 hours remaining. This remarkable achievement highlights the increasing interest from investors in the XRPL's first fully decentralized index fund protocol. The momentum is undeniable as the...

Continue Reading
Sinclair Introduces Innovative AMP Sales and Media Solutions

Updated Category News Views 396

Sinclair Unveils AMP Sales & Marketing Solutions and AMP Media Sinclair Broadcast Group has launched exciting new initiatives, AMP Sales & Marketing Solutions and AMP Media, aimed at transforming its advertising sales and content creation efforts. The introduction of AMP represents a significant step in Sinclair's evolution as it strives to better engage with clients and...

Continue Reading